Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) manufactures radiation therapy and radiosurgery systems for cancer treatment, making its news flow particularly relevant for investors tracking the medical device and oncology equipment sectors. The company's announcements typically include quarterly earnings reports, product launch updates, clinical partnership developments, and regulatory milestones that affect its position in the radiation oncology market.
News coverage for Accuray focuses on several key areas that drive the company's business performance. Product developments include new system installations, technology enhancements to the CyberKnife and TomoTherapy platforms, and software updates that expand treatment capabilities. Clinical partnerships with major cancer centers and academic medical institutions often signal adoption trends and validation of the company's radiosurgery approaches. Financial results provide insight into equipment sales cycles, service contract growth, and the balance between product revenue and recurring service income.
Investors following Accuray also monitor news about regulatory clearances for new indications or system upgrades, strategic initiatives related to market expansion or operational efficiency, and competitive developments in the radiation oncology equipment landscape. The capital-intensive nature of medical device sales means that individual system orders, installation milestones, and service contract renewals can represent material business developments worth tracking.
This news feed aggregates developments specific to Accuray's operations in the precision oncology equipment market, helping investors understand how the company's technology adoption, clinical evidence generation, and commercial execution affect its competitive position. Regular monitoring of earnings reports, product announcements, and partnership news provides context for evaluating the company's progress in the specialized radiosurgery and radiation therapy segment.
Accuray (NASDAQ: ARAY) announced the first phase of a transformation plan on Dec 15, 2025 focused on organizational realignment, cost right-sizing, outsourcing, and sales enablement.
The company expects approximately $25 million of annualized operating profitability improvement, with about $12 million realized in fiscal 2026, and plans to implement nearly all initiatives by fiscal 2026 year-end. Actions include streamlining commercial structure, centralizing core functions, elevating global heads of service and product development to report to the CEO, reallocating engineering resources, and reducing global headcount by roughly 15%. Accuray expects restructuring charges of approximately $11 million across fiscal Q2–Q4 2026, most of which are expected to be cash charges.
Accuray (NASDAQ: ARAY) reported fiscal Q1 2026 results for the quarter ended Sept 30, 2025, and announced executive and transformation actions. Total net revenue was $93.9M (down 7% YoY). Product revenue was $37.2M (down 23% YoY) while service revenue was $56.8M (up 7% YoY). The company recorded $2.8M of restructuring charges and appointed Steve La Neve as CEO.
Profitability: gross profit was $26.5M (28.3% margin) vs $34.5M (33.9%) prior year; net loss was $21.7M or $0.18 per share vs loss $4.0M prior year. Adjusted EBITDA loss was $4.1M. Order backlog was $395.7M (≈16% lower YoY). Cash and equivalents were $63.9M. The company reaffirmed FY2026 guidance: revenue $471M–$485M and adjusted EBITDA $31M–$35M.
Accuray (NASDAQ: ARAY) announced inducement equity awards to new CEO Stephen La Neve effective October 31, 2025, granted outside the company’s existing equity plan under NASDAQ Rule 5635(c)(4).
The board approved 1,500,000 restricted stock units vesting 25% annually over four years and 1,500,000 performance-based restricted stock units (PSUs) tied to VWAP stock-price goals over an approximately six-year performance period ending September 30, 2031. PSUs are split into three tranches with specific price targets and dated vesting cutoffs in 2027, 2029, and 2031.
Accuray (NASDAQ: ARAY) will report first quarter fiscal 2026 financial results for the period ended September 30, 2025 on November 5, 2025. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day.
Dial-in numbers: 1-833-316-0563 (USA) or 1-412-317-5747 (international). A dial-up replay will be available about one hour after the call for one week at 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID 7403898. A live webcast and replay will be available in the Investor Relations section at investors.accuray.com and will remain until Accuray announces second quarter fiscal 2026 results.
Accuray (NASDAQ: ARAY) announced a leadership and board overhaul to accelerate a company-wide transformation, effective October 20, 2025. Steve La Neve was appointed CEO and Suzanne Winter will retire and remain an advisor through November. Steven F. Mayer was named Transformation Board Sponsor and Chan W. Galbato was nominated to the board.
The company provided preliminary fiscal 2026 Q1 figures: total revenues of $92.5–$94.0 million and adjusted EBITDA of approximately ($4) million. Management said service revenues exceeded plan while product revenues missed expectations in EIMEA and China. The Board targets a high single‑digit adjusted EBITDA margin run‑rate within 12 months and double‑digit margins over the medium to long term.
Accuray (NASDAQ: ARAY) announced that 5D Clinics and JV partner Icon Group treated the first patients in Melbourne using the CyberKnife S7 System on October 8, 2025.
The JV plans to open and operate CyberKnife centers across Australia, initially focusing on the East Coast; alphaXRT is the exclusive distributor and supported installation through first patient treatment. The CyberKnife S7 enables 1–5 outpatient SBRT/SRS sessions versus traditional 30–40 fractions, and the press release cites projected new cancer cases in Australia rising ~50% from 2022 to 2045.
Expansion is noted as subject to Australian regulatory approvals.
Accuray (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health have signed a memorandum of understanding to advance online adaptive radiotherapy (OART) on Accuray's helical radiation treatment platform. The collaboration will focus on clinical research, education and training, and adaptive technology development to enhance cancer care personalization and precision.
The partnership is particularly significant as UW-Madison researchers were the original inventors of the TomoTherapy® System, the first helical radiation delivery platform. The system revolutionized radiation medicine by enabling integrated 3D daily image-guidance with intensity-modulated radiation therapy (IG-IMRT). The collaboration aims to make OART more accessible to clinical departments of all sizes while advancing the technology's capabilities.
Accuray (NASDAQ: ARAY) has launched the Accuray Stellar Solution, an advanced all-in-one radiotherapy platform initially for the U.S. market. The solution integrates with the company's Radixact Treatment Delivery System and includes comprehensive tools for adaptive radiotherapy.
The system offers multiple delivery modalities including IMRT, SBRT, and SGRT, targeting various cancer types such as breast, prostate, lung, and head and neck cancers. Key features include ClearRT helical kVCT imaging, Synchrony technology for real-time motion tracking, PreciseART for offline adaptive protocols, and the new Adapt LTE powered by Accuray Cenos for treatment evaluation and training.
Accuray (NASDAQ: ARAY) announced it will host an analyst and investor event during the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco on September 29, 2025. The hybrid event, starting at 1:30 PM PT, will feature global thought leaders discussing adaptive radiotherapy in radiation medicine.
The presentation will cover key topics including the adaptive radiotherapy spectrum, programmatic vision, practice integration, workflow realities, and motion management from a global perspective. Both in-person and virtual attendees must register by September 25, 2025.
Accuray (NASDAQ: ARAY) reported its Q4 and fiscal 2025 results with mixed performance. Q4 revenue decreased 5% to $127.5 million, while full-year revenue grew 3% to $458.5 million. The company posted Q4 net income of $1.1 million compared to $3.4 million in the prior year, while recording a full-year net loss of $1.6 million, improved from a $15.5 million loss in FY24.
Service revenue showed strength with a 4% increase in both Q4 and full-year results. The company successfully completed a debt refinancing and maintained a book-to-bill ratio of 1.2. For FY26, Accuray projects revenue between $471-485 million and adjusted EBITDA of $31-35 million.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
